ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Shionogi in talks with U.S. to supply COVID oral drug

Japanese drugmaker also says vaccine proven effective in trials

Shionogi is set to start clinical trials in the U.S. for its COVID-19 oral therapy.(Nikkei montage/Photos by Tomoki Mera, Shionogi)

OSAKA -- Japanese drugmaker Shionogi & Co. said Friday that it has entered talks with the U.S. government to supply its oral medication for COVID-19 currently in development.

Shionogi is preparing for clinical trials for the drug in the U.S., due to begin this month at the earliest. The pill would be Japan's first domestically developed oral COVID treatment.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more